Merck Reports the US FDA’s Approval of Keytruda Plus Pemetrexed and Platinum Chemotherapy to Treat Malignant Pleural Mesothelioma (MPM)
Shots:
- The US FDA has granted approval to Keytruda in addition to pemetrexed & Pt-based CT as a 1L treatment of unresectable advanced or metastatic MPM
- The approval was based on P-II/III (IND.227/KEYNOTE-483) study assessing the safety & efficacy of the combination, with P-III involving 440 subjects with unresectable advanced or metastatic MPM and no previous systemic therapy, irrespective of tumor PD-L1 expression
- Study showed improved OS and reduced the death risk by 21%, mOS of 17.3mos. vs 16.1mos., improved PFS with mPFS of 7.1mos. in both and ORR of 52% vs 29%
Ref: Merck | Image: Merck
Related News:- GI Innovation Join Forces with Merck to Evaluate GI-102 Plus Keytruda for Treating Various Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
